PATENT CLAIM ANALYSIS

Application Number: 16227820
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "343000"]

Abstract:
The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

Claim (Index 5):
The method of  claim 1 , wherein the second agent is an ERK inhibitor selected from the group consisting of AEZS-131 (Aetema Zentaris), AEZS-136 (Aeterna Zentaris), SCH-722984 (Merck & Co.), SCH772984 (Merck & Co.), SCH-900353 (MK-8353) (Merck & Co.), pharmaceutically acceptable salts thereof, and combinations thereof.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.48276
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15011377', '15011420', '15598181', '15598160', '14821931']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8501642397230603
- 35 USC 102 Novelty (BERT): 0.579477301496365
- Combined Prediction Score: 0.8230955459003908
- Mean Citation Score: 513.4798400000002
- Max Citation Score: 595.12555
- Similarity Product: 354.3844195311368

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test